Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Syros Pharmaceuticals excels in heme programs and strategic collaborations

Syros Pharmaceuticals demonstrated strong performance in heme programs, financial resilience, and strategic collaborations, despite challenges in expenses and net losses.
The company's focus on upcoming catalysts and clinical program advancements presents opportunities for growth and innovation in the competitive biopharmaceutical landscape.
Navigating challenges in trial protocols and financial management, Syros Pharmaceuticals aims to leverage strengths in regulatory designations and partnerships for sustainable growth.

Syros Pharmaceuticals reports Q1 progress in key programs and trials

Syros Pharmaceuticals' Q1 2023 performance reflects ongoing investments in late-stage clinical programs amid revenue generation.
The company's focus on key therapeutic areas and proactive approach to trial protocols position it for potential clinical and regulatory milestones.
While facing challenges in financial performance and the need for clarity on trial-related matters, Syros Pharmaceuticals maintains a solid cash position and promising opportunities ahead.

Syros Pharmaceuticals reports Q2 progress in clinical trials and challenges

Syros Pharmaceuticals' Q2 performance reflects a focus on advancing innovative therapies for MDS and AML amid significant R&D investments.
The company faces challenges in managing financials, decision-making timelines, and balancing investments with revenue generation.
Opportunities lie in the potential of tamibarotene, strategic partnerships, and upcoming data readouts to drive future growth and value creation.

Syros Pharmaceuticals advances tamibarotene for hematologic malignancies under new CEO

Syros Pharmaceuticals is strategically advancing tamibarotene for hematologic malignancies under new leadership, with a strong financial performance in the third quarter. While facing challenges in meeting efficacy data expectations, the company has opportunities to address unmet needs in AML and MDS, positioning itself for growth.

Syros Pharmaceuticals reports positive trial results and secures $45M financing

Syros Pharmaceuticals showcased strong performance in clinical trials and financial management in Q4 2023.
While facing challenges in regulatory aspects and profitability, the company is well-positioned for growth.
Opportunities lie in upcoming trial data, product launches, and strategic initiatives for revenue expansion.
Overall, Syros Pharmaceuticals remains optimistic about its future prospects and market positioning.

Syros Pharmaceuticals advances tamibarotene with FDA Fast Track Designation

Syros Pharmaceuticals showcased progress in clinical development programs, particularly with tamibarotene, and secured FDA Fast Track Designation for AML treatment. Despite no revenue in Q1 2024, the company's financial position remains stable with $108.3 million in cash and extended financial flexibility. Challenges include revenue impact from terminated agreements and the need to navigate market competition.

Syros Pharmaceuticals reports Q2 loss, eyes market expansion opportunities

Syros Pharmaceuticals showcased progress on tamibarotene trials with positive results in MDS and AML.
Financial performance in Q2 2024 reflected a net loss but maintained solid cash reserves for operations.
Analyst inquiries and executive insights highlighted strategic focus on pivotal studies and commercialization plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q2 2019 Results - Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2019 Results - Earnings Call Transcript

Syros plunged 33% on Friday, April 5, after announcing a stock offering.

Syros Pharmaceuticals Platform Undervalued After Dip

The company announced the pricing of a stock offering. Despite the dilution, it's a well-timed move by management.

Here's Why Syros Pharmaceuticals Is Collapsing Today

SYRS earnings call for the period ending December 31, 2018.

Syros Pharmaceuticals, Inc. (SYRS) Q4 2018 Earnings Conference Call Transcript

News for Syros Pharmaceuticals Stock (SYRS)